Perindopril Arginine

ApprovedSmall molecule

YYaounde Central Hospital

Perindopril Arginine is one of 30 small molecule programs targeting Aortic Aneurysm. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic AneurysmActive, not recruiting

Type 2 DiabetesActive, not recruiting

Aortic AneurysmPhase 2

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Perindopril Arginine

YYaounde Central Hospital

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Glargine

Eli Lilly

Preclinical

8 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 10

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aortic Aneurysm1 trial

AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)

Completed·IImperial College London·Phase 2·NCT01118520·224 enrolled

Blood Pressure1 trial

Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients.

Completed·YYaounde Central Hospital·Phase 4·NCT04254042·24 enrolled

Tics1 trial

Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients

Completed·YYaounde Central Hospital·Phase 4·NCT04222686·23 enrolled

Type 2 Diabetes1 trial

Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes

Completed·YYaounde Central Hospital·Phase 4·NCT03747978·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Perindopril Arginine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perindopril Arginine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Perindopril Arginine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yaounde Central Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: YYaounde Central Hospital

Perindopril Arginine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aortic Aneurysm1 trial

Blood Pressure1 trial

Tics1 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News